Dihydrofluoxymesterone

Dihydrofluoxymesterone (developmental code name U-7265) is an androgen and anabolic steroid (AAS) which was never marketed.[1][2][3] It was assessed in the treatment of breast cancer in women in at least one clinical study in the 1970s and showed effectiveness similar to that of other AAS.[1][2] The drug is the 5α-reduced analogue and metabolite of fluoxymesterone.[1][2][3]

Dihydrofluoxymesterone
Clinical data
Other namesU-7265; 5α-Dihydrofluoxymesterone; 9α-Fluoro-11β-hydroxy-17α-methyl-5α-dihydrotestosterone; 9α-Fluoro-11β-hydroxy-17α-methyl-5α-DHT; 9α-Fluoro-11β-hydroxy-17α-methyl-5α-androstan-17β-ol-3-one
Routes of
administration
By mouth
Drug classAndrogen; Anabolic steroid
Chemical and physical data
FormulaC20H30FO3
Molar mass337.454 g/mol g·mol−1
3D model (JSmol)

See also

References

  1. Gordan, G. S. (1976). "Cancer in Man": 499–513. doi:10.1007/978-3-642-66353-6_16. Cite journal requires |journal= (help)
  2. Charles D. Kochakian (6 December 2012). Anabolic-Androgenic Steroids. Springer Science & Business Media. pp. 504–. ISBN 978-3-642-66353-6.
  3. Kammerer RC, Merdink JL, Jagels M, Catlin DH, Hui KK (1990). "Testing for fluoxymesterone (Halotestin) administration to man: identification of urinary metabolites by gas chromatography-mass spectrometry". J. Steroid Biochem. 36 (6): 659–66. doi:10.1016/0022-4731(90)90185-u. PMID 2214783.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.